Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

David G DeNardo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3655-5783; OpenAlex author ID A5066901504; NIH RePORTER profile ID 8710339. Sources: funder_awards.

Their work

Papers
43 (first author 1, last author 13)
Trials
0
Grants
14
Labs led
1
Collaborators
120
Papers, trials and grants by year

2013: 3 papers · 2014: 2 papers, 1 grant · 2015: 1 grant · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers, 2 grants · 2021: 1 paper · 2022: 6 papers · 2023: 6 papers, 1 grant · 2024: 5 papers, 2 grants · 2025: 4 papers, 1 grant · 2026: 5 papers, 6 grants

Papers 43

  1. Adaptive Salvage Stereotactic Radiation for Locoregional Recurrence of Pancreatic Adenocarcinoma After Surgery. Co-author DOI 10.1016/j.prro.2026.03.015↗
  2. Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.017↗
  3. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Co-author DOI 10.1126/sciimmunol.adz4302↗
  4. Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic. Co-author DOI 10.1186/s12943-026-02597-7↗
  5. Multi-modal spatial glycomic analysis of lymphoid aggregates in prostate and pancreatic cancer tissues. Co-author DOI 10.3389/fonc.2026.1935795↗
  6. Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade Co-author DOI 10.1101/2025.10.08.681226↗
  7. Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer. Last author DOI 10.1126/sciimmunol.adp3978↗
  8. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1821↗
  9. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  10. Targeting dendritic cells to drive PDAC immunotherapy response. First author DOI 10.1016/j.tips.2024.10.009↗
  11. Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acsptsci.3c00303↗
  12. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
  13. Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2024.2320411↗
  14. Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-23-0428↗
  15. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
  16. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Last author DOI 10.1038/s41590-023-01579-x↗
  17. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. Co-author DOI 10.1038/s41698-023-00455-z↗
  18. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Last author DOI 10.1084/jem.20212062↗
  19. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Last author DOI 10.1158/1078-0432.ccr-23-2993↗
  20. Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-21-0946↗
  21. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
  22. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.02.035↗
  23. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Last author DOI 10.1158/1078-0432.ccr-22-0308↗
  24. Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.150330↗
  25. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1039226↗
  26. Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS. Co-author DOI 10.3390/cancers14092153↗
  27. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0998↗
  28. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Last author DOI 10.1016/j.ccell.2020.02.008↗
  29. Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor. Co-author DOI 10.1097/pas.0000000000001454↗
  30. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Last author DOI 10.1136/gutjnl-2018-317424↗
  31. B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0349↗
  32. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Last author DOI 10.1126/scitranslmed.aau9240↗
  33. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Last author DOI 10.1038/s41467-018-03600-6↗
  34. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic du… Co-author DOI 10.1136/gutjnl-2017-313738↗
  35. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Last author DOI 10.1016/j.immuni.2017.07.014↗
  36. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-16-1121↗
  37. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  38. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Co-author DOI 10.18632/oncotarget.9551↗
  39. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Co-author DOI 10.1007/s00262-014-1527-x↗
  40. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Last author DOI 10.1158/0008-5472.can-13-3723↗
  41. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Co-author DOI 10.1158/1078-0432.ccr-13-0525↗
  42. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. Co-author DOI 10.1371/journal.pone.0077243↗
  43. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4236/jct.2013.43096↗

Grants 14

  1. Catalyst Research Award (Precision Promise biospecimens and data): David DeNardo AWARD pancan:2026-david-denardo-catalyst-research-award-precision-promis
  2. Core A: Administrative Core P50CA272213↗
  3. Stomal Senescence Regulator of Tumor Immunity and Progression R01CA286615↗
  4. Targeting Tumor Intrinsic and Extrinsic Survival Signaling to Overcome Resistance to Radiation Therapy in Pancreatic Cancer. R01CA303033↗
  5. The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity U01CA284086↗
  6. METEOR-Comprehensive Radiobiology Assessment TRial (METEOR-CRATR) U54CA274318↗
  7. Re-wiring PDAC Tumor Immunity Through Dendritic Cells R01CA262506↗
  8. Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy R01CA244938↗
  9. Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity R01CA248917↗
  10. The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer R01CA177670↗
  11. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
  12. COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY R01CA203890↗
  13. TARGETING CCR2 TO OVERCOME IMMUNOSUPPRESSION AND IMPROVE IMMUNOTHERAPY R21CA182701↗
  14. Origins and Impact of Macrophages in Pancreatic Cancer AWARD pancan:2014-david-denardo-phd-origins-and-impact-of-macrophages-in-pan

Closest collaborators

The 25 strongest of 120 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryan C Fields · 21 shared papers, 3 shared grants, 2013–2026 · strength 4.73
  2. William G. Hawkins · 23 shared papers, 2 shared grants, 2013–2026 · strength 3.52
  3. Kian‐Huat Lim · 15 shared papers, 1 shared grant, 2016–2026 · strength 3.05
  4. Liang‐I Kang · 11 shared papers, 2020–2026 · strength 1.97
  5. Patrick M. Grierson · 4 shared papers, 1 shared grant, 2022–2026 · strength 1.73
  6. Hyun Kim · 2 shared grants, 2024–2026 · strength 1.72
  7. Li Ding · 4 shared papers, 1 shared grant, 2023–2026 · strength 1.60
  8. Paolo Provenzano · 2 shared papers, 1 shared grant, 2022–2026 · strength 1.57
  9. William E. Gillanders · 4 shared papers, 2 shared grants, 2018–2026 · strength 1.49
  10. Carl DeSelm · 2 shared papers, 1 shared grant, 2020–2026 · strength 1.41
  11. Clifford Grant Robinson · 1 shared grant, 2026 · strength 1.26
  12. Vikas Somani · 6 shared papers, 2022–2026 · strength 1.21
  13. Andrea Wang‐Gillam · 11 shared papers, 1 shared grant, 2013–2025 · strength 1.12
  14. Graham D. Hogg · 8 shared papers, 2019–2025 · strength 1.10
  15. John M. Baer · 8 shared papers, 2018–2025 · strength 1.09
  16. Vineet Gupta · 1 shared grant, 2024 · strength 0.91
  17. Sapana Bansod · 4 shared papers, 2024–2026 · strength 0.90
  18. Julie Kristina Schwarz · 2 shared papers, 1 shared grant, 2019–2024 · strength 0.89
  19. Varintra E. Lander · 6 shared papers, 2020–2025 · strength 0.87
  20. Roheena Z. Panni · 9 shared papers, 2013–2026 · strength 0.80
  21. Chong Zuo · 7 shared papers, 2017–2023 · strength 0.76
  22. C. Alston James · 5 shared papers, 2021–2024 · strength 0.74
  23. Ashenafi Shiferaw Bulle · 3 shared papers, 2024–2026 · strength 0.65
  24. Alyssa G. Weinstein · 2 shared papers, 2024–2025 · strength 0.64
  25. Albert Craig Lockhart · 5 shared papers, 1 shared grant, 2013–2023 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.